Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.

Kushner BH, Ostrovnaya I, Cheung IY, Kuk D, Modak S, Kramer K, Roberts SS, Basu EM, Yataghene K, Cheung NK.

Oncotarget. 2016 Jan 26;7(4):4155-66. doi: 10.18632/oncotarget.6393.

2.

Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells.

Tsao CY, Sabbatino F, Cheung NV, Hsu JC, Villani V, Wang X, Ferrone S.

Oncoimmunology. 2015 Apr 2;4(8):e1023975.

3.

Tumor-Associated Glycans and Immune Surveillance.

Monzavi-Karbassi B, Pashov A, Kieber-Emmons T.

Vaccines (Basel). 2013 Jun 17;1(2):174-203. doi: 10.3390/vaccines1020174. Review.

4.

Enhancing Cancer Immunotherapy Via Activation of Innate Immunity.

Goldberg JL, Sondel PM.

Semin Oncol. 2015 Aug;42(4):562-72. doi: 10.1053/j.seminoncol.2015.05.012. Review.

5.

Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study.

Kushner BH, Ostrovnaya I, Cheung IY, Kuk D, Kramer K, Modak S, Yataghene K, Cheung NK.

Oncoimmunology. 2015 May 22;4(7):e1016704.

6.

Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy.

Cheung NK, Ostrovnaya I, Kuk D, Cheung IY.

J Clin Oncol. 2015 Mar 1;33(7):755-63. doi: 10.1200/JCO.2014.57.6777.

7.

GD2-targeted immunotherapy and radioimmunotherapy.

Dobrenkov K, Cheung NK.

Semin Oncol. 2014 Oct;41(5):589-612. doi: 10.1053/j.seminoncol.2014.07.003. Review.

8.

Outcomes After Radiation Therapy to Metastatic Sites in Patients With Stage 4 Neuroblastoma.

Kandula S, Prabhu RS, Nanda R, Switchenko JM, Cash T, Qayed M, Katzenstein H, Esiashvili N.

J Pediatr Hematol Oncol. 2015 Apr;37(3):175-80. doi: 10.1097/MPH.0000000000000264.

9.

Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study.

Ladenstein R, Weixler S, Baykan B, Bleeke M, Kunert R, Katinger D, Pribill I, Glander P, Bauer S, Pistoia V, Michon J, Garaventa A, Lode HN.

MAbs. 2013 Sep-Oct;5(5):801-9. doi: 10.4161/mabs.25215.

10.

Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan: A Phase I study in patients with chemoresistant neuroblastoma.

Modak S, Kushner BH, Kramer K, Vickers A, Cheung IY, Cheung NK.

Oncoimmunology. 2013 Mar 1;2(3):e23402.

11.

Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody.

Kushner BH, Modak S, Basu EM, Roberts SS, Kramer K, Cheung NK.

Cancer. 2013 Aug 1;119(15):2789-95. doi: 10.1002/cncr.28137.

12.

Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment.

Leal T, Chang JE, Mehta M, Robins HI.

Curr Cancer Ther Rev. 2011 Nov;7(4):319-327.

13.

Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.

Cheung NK, Cheung IY, Kushner BH, Ostrovnaya I, Chamberlain E, Kramer K, Modak S.

J Clin Oncol. 2012 Sep 10;30(26):3264-70. doi: 10.1200/JCO.2011.41.3807.

14.

Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment.

Tarek N, Le Luduec JB, Gallagher MM, Zheng J, Venstrom JM, Chamberlain E, Modak S, Heller G, Dupont B, Cheung NK, Hsu KC.

J Clin Invest. 2012 Sep;122(9):3260-70. doi: 10.1172/JCI62749.

15.

Anti-CD3 × anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets.

Yankelevich M, Kondadasula SV, Thakur A, Buck S, Cheung NK, Lum LG.

Pediatr Blood Cancer. 2012 Dec 15;59(7):1198-205. doi: 10.1002/pbc.24237.

16.

Promising therapeutic targets in neuroblastoma.

Matthay KK, George RE, Yu AL.

Clin Cancer Res. 2012 May 15;18(10):2740-53. doi: 10.1158/1078-0432.CCR-11-1939. Review.

17.

Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites.

Ott MG, Marmé F, Moldenhauer G, Lindhofer H, Hennig M, Spannagl R, Essing MM, Linke R, Seimetz D.

Int J Cancer. 2012 May 1;130(9):2195-203. doi: 10.1002/ijc.26258.

18.

Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study.

Kushner BH, Kramer K, Modak S, Cheung NK.

J Clin Oncol. 2011 Mar 20;29(9):1168-74. doi: 10.1200/JCO.2010.28.3317.

19.

Anti-GD2 Strategy in the Treatment of Neuroblastoma.

Yang RK, Sondel PM.

Drugs Future. 2010;35(8):665.

20.

Preliminary results of a phase I trial of prophylactic ethanol-lock administration to prevent mediport catheter-related bloodstream infections.

Kayton ML, Garmey EG, Ishill NM, Cheung NK, Kushner BH, Kramer K, Modak S, Rossetto C, Hennelly C, Doyle MP, Rosenberg S, Santoro O, La Quaglia MP.

J Pediatr Surg. 2010 Oct;45(10):1961-6. doi: 10.1016/j.jpedsurg.2010.05.014.

Items per page

Supplemental Content

Support Center